Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic ...

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis. “Skin biopsies from the head-to-head Level Up study showed broader effects on ...

The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.

In a recent interview with Dermatology Times, Whitney Tolpinrud, MD, board-certified dermatologist and chief dermatologist at Curology, discussed the evolution of personalized prescription dermatology ...

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.

Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...

Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the ...

Patient-reported burden improved in adults, with DLQI dropping from 14.5 to 7.9 and itch/pain numerical rating scales ...

In this Expert Perspectives video, Andrew Blauvelt, MD, MBA, discusses emerging efficacy data for targeted oral psoriasis therapies and how clinicians can interpret head-to-head t ...

Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...

Celltrion USA announced on October 5, 2026, that Omlyclo (omalizumab-igec), the first FDA-approved interchangeable biosimilar ...

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.